Explore 23andMe genetic reports.
Take some time to download the report examples that interest you to better understand the types of information your patients receive and may wish to share with you.
Take some time to download the report examples that interest you to better understand the types of information your patients receive and may wish to share with you.
The Health Predispositions category includes both reports that meet FDA requirements for Genetic Health Risks and reports Powered by 23andMe Research. These reports are not intended to tell a person anything about his or her current state of health, or to be used to make medical decisions.
Those with a personal or family history of any of these conditions should speak with their healthcare provider to determine if comprehensive genetic testing is appropriate.
Each Genetic Health Risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. These reports are not intended to tell a person anything about his or her current state of health, or to be used to make medical decisions, including whether or not he or she should take a medication or how much of a medication should be taken.
Genetic Health Risk reports package insert
White Paper 23-15: Scientific Standards for 23andMe’s Health and Trait Reports
Variant(s) detected
Your patient has one or more of the variants we tested. They may be at increased risk for the condition based on this result. This doesn’t mean s/he will definitely develop the condition. Other factors may also affect their risk.
Result not determined
Your patient’s test result could not be determined. This can be caused by random test error or other factors that interfere with the test.
Reports that are “Powered by 23andMe Research” are developed using data and insights gathered from thousands of customers who consented to participate in our research.
White Paper 23-19: The Science Behind 23andMe’s Type 2 Diabetes Report
White Paper 23-21: A Generalized Method for the Creation and Evaluation of Polygenic Scores
| POLYGENIC REPORTS | VARIANTS CONTRIBUTING TO MODEL | RELEVANT ETHNICITIES |
|---|---|---|
Report
|
Variants2000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
|
Report
|
Variants2000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants2100+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants6900+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants6000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants21,000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants15,800+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
|
Report
|
Variants2000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants20,000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
|
Report
|
Variants2000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants20,000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants1400+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants23,000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants1300+ | Relevant Ethnicities European, Hispanic/ Latino, East/Southeast Asian, South Asian, Sub-Saharan African/ African American, Northern African/Central and Western Asian descent |
| Report | Variants23,000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants8500+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
| Report | Variants7400+ | Relevant Ethnicities European, Hispanic/ Latino, East/Southeast Asian, South Asian, Sub-Saharan African/ African American, Northern African/Central and Western Asian descent |
|
Report
|
Variants1000+ | Relevant Ethnicities European, Hispanic/Latino, African, East Asian, South Asian |
| Report | Variants1000+ | Relevant Ethnicities European, Hispanic/Latino, East/Southeast Asian, South Asian, Sub-Saharan African/African American, Northern African/Central and Western Asian descent |
These reports include specific variants that can impact the body’s ability to process certain medications. These reports include a subset of possible variants involved in medication processing and provides interpretative drug information about how specific DNA variants may impact Clopidogrel and Citalopram therapy based on the CYP2C19 result. 23andMe’s FDA clearance of these new reports also removes the need for confirmatory testing in a clinical setting for specific CYP2C19 outcomes.
Pharmacogenetics reports package inserts
White paper 23-15: Scientific standards for 23andMe’s Health and Traits Reports
Variant(s) detected
You may have one or more of the variant(s) we tested. The variant(s) may affect how your body processes certain medications. However, since many factors impact how medications are processed, the detected variant(s) may have no noticeable effect.
Result not determined
Your test result could not be determined. This can be caused by random test error or other factors that interfere with the test.
In very rare cases, we may not be able to interpret your genetic result. Talk to a healthcare professional to learn more about how DNA variants may influence your body’s ability to process medications.
These reports include genetic variants that have been linked to recessive conditions and provide insight into carrier status for the conditions listed below. These reports include only a subset of possible variants that may be linked to a condition, and it is possible to have other variants not included in these reports. Those with a family history of any of these conditions or increased risk based on ethnicity or family origin and are considering having children should discuss options for comprehensive testing with their healthcare provider.
Note: Sample reports do not cover all possible test result outcomes, and for many reports, residual risk estimates vary by ethnicity.
Your patient does not have the variant(s) we tested. There is still a chance that the patient could have a variant not covered by this test.
1 Variant
Your patient is a carrier and could pass the variant on to each of their children.
2 Variants††
Your patient will most likely pass a variant on to each of their children.
Result not determined
Your patient’s test result could not be determined. This can be caused by random test error or other factors that interfere with the test.
† For some reports, a customer may receive a result indicating that they have two copies of a variant. In these cases, the customer will pass a variant on to each of his or her children.
†† For some reports, customers with two copies of a variant will also be told that they are at risk for developing symptoms of the condition.
These reports describe how genetics influence traits and conditions related to lifestyle and environment.
White Paper 23-17: The Science Behind 23andMe’s Genetic Weight Report
White Paper 23-15: Scientific Standards for 23andMe’s Health and Trait Reports
These reports help consumers learn about their origins and ancient ancestors based on their DNA.
White Paper 23-16: Ancestry Composition: A Novel, Efficient Pipeline for Ancestry Deconvolution
White Paper 23-05: Neanderthal Ancestry Inference
These reports are a fun way for consumers to learn about how genetics influence traits like eye color, hair texture and taste preference.
White Paper 23-15: Scientific Standards for 23andMe’s Health and Trait Reports
Our customers have access to their raw genetic data, which they can view or download from their 23andMe account. This data has undergone a general quality review; however, only a subset of markers have been individually validated for accuracy. As such, the data from 23andMe’s Browse Raw Data feature is suitable only for research and educational and informational use and not for medical, diagnostic or other use.
The raw data could include sensitive information. Within the data, your patients could discover sensitive information about themselves and family members with whom they share their DNA. For example, comparing data between family members could reveal misattributed paternity.
*The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet US FDA requirements for genetic health risks and the 23andMe Type 2 Diabetes health predisposition report which is based on 23andMe research and has not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. The MUTYH-Associated Polyposis Genetic Health Risk Report is indicated for reporting the Y179C and G396D variants in the MUTYH gene and an increased risk for colorectal cancer. The two variants included in this report are most common in people of Northern European descent. These reports do not include variants in other genes linked to hereditary cancers and the absence of variants included in these reports do not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding other genetic health risk reports and carrier status reports, visit 23andme.com/test-info.
The 23andMe PGS test uses qualitative genotyping to detect 6 variants in 3 genes in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Results should be confirmed in a clinical setting with independent genetic testing before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For a complete list of the 6 variants tested, visit https://permalinks.23andme.com/pdf/pgt_product_info_page_21jan2020.pdf.
23andMe’s New Pharmacogenetics Reports (24 minutes)